183 related articles for article (PubMed ID: 8033095)
21. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast.
Visscher DW; Sarkar FH; Wykes S; Kothari K; Macoska J; Crissman J
Arch Pathol Lab Med; 1993 Oct; 117(10):973-6. PubMed ID: 8215837
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
Zhang Hong
Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
[TBL] [Abstract][Full Text] [Related]
24. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
25. Heat-shock protein 70 as a prognostic marker in node-negative breast cancer.
Thanner F; Sütterlin MW; Kapp M; Rieger L; Kristen P; Dietl J; Gassel AM; Müller T
Anticancer Res; 2003; 23(2A):1057-62. PubMed ID: 12820347
[TBL] [Abstract][Full Text] [Related]
26. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R
Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
28. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
[TBL] [Abstract][Full Text] [Related]
29. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
30. Expression of heat shock protein 70 and c-myc protein in human breast cancer: an immunohistochemical study.
Tauchi K; Tsutsumi Y; Hori S; Yoshimura S; Osamura RY; Watanabe K
Jpn J Clin Oncol; 1991 Aug; 21(4):256-63. PubMed ID: 1658414
[TBL] [Abstract][Full Text] [Related]
31. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma.
Visscher DW; Sarkar F; Tabaczka P; Crissman J
Mod Pathol; 1996 Jun; 9(6):642-6. PubMed ID: 8782201
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer].
Fan P; Wu Z; Cha X; Wang X; Wang S
Zhonghua Wai Ke Za Zhi; 1998 Nov; 36(11):655-7. PubMed ID: 11825490
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases.
Frankfurt OS; Robb JA; Sugarbaker EV; Villa L
Clin Cancer Res; 1997 Mar; 3(3):465-71. PubMed ID: 9815706
[TBL] [Abstract][Full Text] [Related]
35. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
36. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
38. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
39. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.
Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J
Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868
[TBL] [Abstract][Full Text] [Related]
40. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study.
Ostrowski JL; Sawan A; Henry L; Wright C; Henry JA; Hennessy C; Lennard TJ; Angus B; Horne CH
J Pathol; 1991 May; 164(1):75-81. PubMed ID: 2056391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
